|Category||Drug Discovery Research||Job type||Full-Time|
Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis.
Join us and make a difference. We hire the best people and provide them with a work environment that places a premium on diversity, integrity, collaboration and personal development. Through a culture of inclusion, we create a better, more productive work environment. We believe that the diverse experiences and perspectives of all our employees help to drive innovation and transformative business results.
The Head of Translational Development for the Mechanisms of Cancer Resistance (MoCR) Thematic Research Center (TRC) will be responsible for developing the translational research and clinical biomarker strategy in alignment with both discovery and early clinical development objectives, as well as clinic-ready target engagement and pharmacodynamic biomarker assays for all therapeutic candidates within the MoCR TRC. This strategy will influence initial patient selection or stratification hypotheses for preclinical drug development programs within the MoCR TRC which develops therapeutic targets at the intersection of tumor, stromal and immune biology to enhance responsiveness to checkpoint blockade or overcome resistance to current treatments.
Roles & Responsibilities
Lead a team of approximately 10-15 scientists and effectively collaborate with other MoCR TRC discovery scientists as well as colleagues in supportive line functions (including discovery biotherapeutics, translational medicine, early clinical development and project leadership) to advance preclinical development of therapeutic candidates and develop high quality biomarker strategies as well as clinic-ready companion target engagement and pharmacodynamics (proximal and distal) biomarker assays for all development candidate programs within the TRC.
Primarily accountable for the development of clinical grade target engagement and patient stratification assays (as required) and deploying in Early Clinical Trials through a combination of internal efforts and alliances with external partners.
Role will partner with the Discovery Leads to ensure that the tools that will be necessary for early clinical decision making are developed in parallel with the chemical matter, starting as early as Lead Optimization.
As a key member of MoCR TRC leadership team role is jointly responsible for oversight of TRC portfolio of programs and collaborations
Ensures the output of the biomarker plans meets established program standards (within budget, on schedule, compliance, etc.), while also looking for opportunities to streamline progress without compromising quality.
This function will also encompass the individuals that will serve as program biomarker leads, in collaboration with the Translational Development and Precision Medicine organization, as programs emerging from the TRC move through early clinical development.
Working with Early Clinical Development and Project Leadership colleagues, proactively sets the strategy and provides insight into novel ways to incorporate biomarkers into clinical designs to enable early understanding of emerging drug profiles.
Communicates key biomarker program information, risks, and milestones, and manages information flow across key stakeholders including therapeutic area leadership, functional leads and team members.
Play a key role in providing the relevant strategic translational input to discovery projects as part of interdisciplinary teams comprising research biology, bioinformatics, histopathology and genomics, with a particular emphasis on human tumor intrinsic biology, to increase the probability of technical success of tumor targeting agents or combinations thereof in patients that are resistant to checkpoint blockade therapy
Scope of Role and Responsibilities
MoCR TRC portfolio mechanism of action, disease biology and translational hypothesis support
Tumor explant / histoculture assays to generate PD and MoA data in context relevant to primary human disease
Development of clinic-ready patient selection and PD assays
Oversee the execution of exploratory biomarker assays
MD, PhD or MD/PhD in Cancer Biology, Immuno-Oncology or equivalent advanced biology degree
Experienced scientist with 12+ years of post-graduate experience in drug development, with a minimum of 5 years in a translational setting
Candidate should have an established track record for leading biomarker development and clinical implementation efforts in Oncology or other related areas.
Deep understanding of the role of translational research/medicine and clinical biomarkers in drug development.
Experience in the design and generation of clinic-ready biomarker assays in the field of Oncology
Bristol-Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees the resources to pursue their goals, both at work and in their personal lives.